1-877-936-8422
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
The goal of this phase I clinical trial is to evaluate the usefulness of an imaging test (zirconium Zr89 panitumumab \[89Zr panitumumab\]) with positron emission tomography (PET)/computed tomography (CT) for diagnosing the spread of disease from where it first started (primary site) to other places in the body (metastasis) in patients with head and neck squamous cell carcinoma. Traditional PET/CT has a low positive predictive value for diagnosing metastatic disease in head and neck cancer. 89Zr panitumumab is an investigational imaging agent that contains radiolabeled anti-EGFR antibody which is overexpressed in head and neck cancer. The main question this study aims to answer is the sensitivity and specificity of 89Zr panitumumab for the detection of indeterminate metastatic lesions in head and neck cancer. Participants will receive 89Zr panitumumab infusion and undergo 89Zr panitumumab PET/CT 1 to 5 days after infusion. Participants will otherwise receive standard of care evaluation and treatment for their indeterminate lesions. Researchers will compare the 89Zr panitumumab to standard of care imaging modalities (magnetic resonance imaging (MRI), CT, and/or PET/CT).
The purpose of this study is to determine if panitumumab-IRDye800 is effective in identifying cancer, compared to surrounding normal tissue, and the further characterize the safety profile of this drug.
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
left
right

About the Summer Experience Program

  • Huntsman Cancer Institute
  • Massey Cancer Center
  • Case Comprehensive Cancer Center
  • The James (The Ohio State University Comprehensive Cancer Center)
  • Vanderbilt-Ingram Cancer Center
  • Virtual, hands-on cancer research experience with laboratory kit sent to your home
  • Targeted career development and skill-building workshops with professionals from diverse sectors of cancer research and care
  • Network of peers and mentors across program sites
  • $500 stipend for participation
  • Must be a rising high school sophomore, junior, or senior within the VICC catchment area
  • Must commit to 4 hours of virtual meetings Monday through Friday for two weeks in the summer during the specified dates
  • Students who are interested in scientific investigation and eager to learn will benefit most from the program.

July 6, 2026, to July 17, 2026. Monday- Friday, 9:30 am - 1:30 pm CDT.

The application deadline for the summer 2026 program is January 5, 2026, by 11:59 PM (CST). Vanderbilt-Ingram Cancer Center will accept 30 students for the 2026 program. Eligible and interested students are asked to complete an application that includes a statement of interest and a letter of recommendation from a science teacher. To apply, access the 2026 application here: https://redcap.link/SHE2026

For more information, please email SHE@vumc.org.

Click here to view an informational sheet for teachers and school staff.

  • “When will I learn if I have been accepted to the program?
    • Emails will be sent out in May from SHE@vumc.org regarding admission decisions for the 2026 program.
  • What counties are included in the VICC catchment area?
    • Vanderbilt-Ingram Cancer Center’s catchment area consists of the entire state of Tennessee, northern Alabama, and southern Kentucky. Please find VICC’s catchment area illustrated below: A map of the state of tennessee AI-generated content may be incorrect.
  • I live outside the catchment area. Can I still apply?
  • I am not a rising sophomore, junior, or senior in high school. What other opportunities are available to me?
  • I have a conflict with some of the program dates. Can I still apply?
    • No, program participants are expected to attend all program dates for the duration of the 2-week program. Your application will not be eligible for review if you cannot attend all program dates.
  • How will I know if my application is NOT complete?
    • You will receive an email from SHE@vumc.org one week before the application deadline if your application is missing any pieces.
  • Have more questions? Reach out to she@vumc.org.

About the VERTICAL Program

Leveraging the strengths of the Vanderbilt-Ingram Cancer Center, Vanderbilt University, and Vanderbilt University Medical Center, this paid program will immerse you in a research laboratory for 2 years working with a Vanderbilt faculty member on a cutting-edge cancer research project.

Participants will receive a stipend and benefits. Through this program you will gain the knowledge, skills, and community to further your career in cancer research or medicine.

In addition to your research, fellows will participate in:

  • Responsible Conduct in Research training
  • Interdisciplinary Graduate Program (IGP) coursework
  • Individualized research development plan
  • Introduction to Cancer Biology course
  • Clinical Cancer Medicine course
  • GRE or MCAT preparatory course
  • Meharry Medical College (MMC)-Vanderbilt-Tennessee State University (TSU) Cancer Partnership (MVTCP) online modules
  • Cancer Biology Science Hour presentation
  • VICC Annual Scientific Retreat, MVTCP retreat, and other retreats
  • Scientific conferences
  • Career Path Lunch & Learn Sessions
  • Online resources from Vanderbilt University, Nature Masterclass
  • Science & Community Impact Talks
  • Volunteer opportunities

 

Eligible candidates for the VERTICAL program will be:

  • Individuals with bachelor’s degrees from nationally accredited colleges or universities who desire to pursue doctoral degrees and careers in science or medicine, with a focus on cancer.
  • Able to commit to the full-time, 2-year program which runs from August 2026– August 2028 in Nashville, Tennessee.
  • Individuals who are interested in pursuing doctoral degrees and careers in science or medicine, with a focus on cancer, will benefit most from the program.

Thank you for your interest in the VERTICAL Program. Applications are currently closed. Please check back here for the next application window.

All program questions should be directed to VERTICAL@vumc.org.

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI, Novartis Pharmaceuticals Corporation). Treatment Group 2: Palazestrant (OP-1250) in combination with alpelisib (PIQRAY, Novartis Pharmaceuticals Corporation). Treatment Group 3: Palazestrant (OP-1250) in combination with everolimus. Treatment Group 4: Palazestrant (OP-1250) in combination with atirmociclib.

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Subscribe to
NCI Designated Cancer Center
NCCN National Comprehensive Cancer Network
NCI National Clinical Trials Network